menu
    • menu
    [{"orgOrder":0,"company":"Link Cell Therapies","sponsor":"Johnson & Johnson Innovative Medicine|Samsara BioCapital|Sheatree Capital|Wing Venture Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Series A Financing","leadProduct":"LNK001","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Link Cell Therapies","amount2":0.059999999999999998,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Link Cell Therapies \/ Johnson & Johnson Innovative Medicine|Samsara BioCapital|Sheatree Capital|Wing Venture Capital","highestDevelopmentStatusID":"5","companyTruncated":"Link Cell Therapies \/ Johnson & Johnson Innovative Medicine|Samsara BioCapital|Sheatree Capital|Wing Venture Capital"}]

    Find Clinical Drug Pipeline Developments & Deals by Link Cell Therapies

    Menu

    Link Cell Therapies

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Link Cell Therapies

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed

                            Link Cell Therapies

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LNK001

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Johnson & Johnson Innovative Medicine|Samsara BioCapital|Sheatree Capital|Wing Venture Capital

                            Deal Size : $60.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Link Cell Therapies Launches Advancing CAR-T in Solid and Liquid Tumors

                            Details : The Series A financing for LNK001, a cell & gene therapy targeting renal cell carcinoma, will advance research in this Renal Cell Carcinoma.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            December 15, 2025

                            Lead Product(s) : LNK001

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Johnson & Johnson Innovative Medicine|Samsara BioCapital|Sheatree Capital|Wing Venture Capital

                            Deal Size : $60.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            • Privacy policy
                            • Terms and conditions
                            • Disclaimers
                            • LinkedIn
                            • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.